Skip to main content

Do We Need Some Large, Simple Randomized Trials in Medicine?

  • Chapter
  • First Online:
EPSA Philosophical Issues in the Sciences

Abstract

In a randomized clinical trial (RCT), a group of patients, initially assembled through a mixture of deliberation (involving explicit inclusion and exclusion criteria) and serendipity (which patients happen to walk into which doctor’s clinic while the trial is in progress), are divided by some random process into an experimental group (members of which will receive the therapy under test) and a control group (members of which will receive some other treatment – perhaps placebo, perhaps the currently standard treatment for the condition at issue). In a ‘double blind’ trial neither the patient nor the clinician knows to which of the groups a particular patient belongs. The results of double blind randomized controlled trials are almost universally regarded as providing the ‘gold standard’ for evidence in medicine. Fairly extreme claims to this effect can be found in the literature. For example the statistician Tukey wrote (1977, p. 679) “almost the only source of reliable evidence [in medicine] is that obtained from carefully conducted randomised trials”. And the clinician Victor Herbert claimed (1977, p. 690) “the only source of reliable evidence rising to the level of proof about the usefulness of any new therapy is that obtained from well-planned and carefully conducted randomized, and, where possible, coded (double blind) clinical trials. [Other] studies may point in a direction, but cannot be evidence as lawyers use the term evidence to mean something probative [that is] tending to prove or actually proving”. Finally, the still very influential movement in favour of ‘Evidence Based Medicine’ (EBM) that began at McMaster University in the 1980s was initially often regarded as endorsing the claim that only RCTs provide real scientifically telling evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    A 2002 study identified no less than 40 such systems of grading evidence (Agency for Healthcare Research and Quality. 2002. Systems to rate the strength of scientific evidence. Rockville MD:AHRQ,); while a 2006 survey found 20 more (Schünemann, Holger J., Atle Fretheim and Andrew D. Oxman. 2006. Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations. Health Research Policy and Systems. 4:21).

  2. 2.

    Meta-analyses and systematic reviews are attempts to amalgamate different studies on the ‘same’ intervention into one overall result. They face many interesting methodological problems.

  3. 3.

    Worrall (2002, 2007a, b, 2008).

  4. 4.

    For references and an especially clear account of this argument of Fisher’s – together with an especially clear demonstration that the argument fails even on its own terms, see Howson (2000).

  5. 5.

    So for example the Director of the UK Cochrane Centre, Mike Clarke, states on the Centre’s Web-site that “[i]n a randomised trial, the only difference between the two groups being compared is that of most interest: the intervention under investigation.” http://209.211.250.105/docs/whycc.htm. Accessed 18 December 2008.

  6. 6.

    See in particular Worrall (2007a) and references therein.

  7. 7.

    So for example Bartlett and colleagues who introduced ECMO as a treatment for PHSS simply switched from treating all babies admitted to their hospital (U of Michigan) with the condition with the previously standard treatment to treating all babies admitted to their hospital with ECMO. No selection! (Though certainly the issue of treatment bias is a genuine one.) See Worrall (2008).

  8. 8.

    See Bradford Hill op. cit.

  9. 9.

    See Worrall (2008).

  10. 10.

    See Worrall (2007b) and the list in Rawlins (2008).

  11. 11.

    These numbers are taken from (and my treatment influenced by) Penston (2003).

  12. 12.

    Lancet 371, 2008, pp. 1665 and 1685.

  13. 13.

    Rawlins (op. cit., p. 16).

  14. 14.

    Of course ‘effectiveness’ is a tricky notion too – positive effect on the ‘target disorder’ is only part of the story, side effects need to be taken into account too.

  15. 15.

    For details and references see Penston (2003).

  16. 16.

    Taken from Penston op. cit.

  17. 17.

    Figures again taken from Penston op. cit.

References

  • Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, Dieppe P (2005) The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess 9:1–152

    Google Scholar 

  • Doll R, Peto R (1980). Randomised controlled trials and retrospective controls. Br Med J 280:44

    Article  Google Scholar 

  • Glaziou P, Chalmers I, Rawlins M, McCulloch P (2007) When are randomised trials unnecessary? Picking signal from noise. Br Med J 334:349–351

    Article  Google Scholar 

  • Hill AB (1937) Principles of medical statistics, 1st edn. in 1937, 9th edn in 1971. Livingstone, London

    Google Scholar 

  • Herbert V (1977) Acquiring new information while retaining old ethics. Science 198:690–693

    Article  Google Scholar 

  • Howson C (2000) Hume’s problem: Induction and the justification of belief. Oxford University Press, Oxford

    Google Scholar 

  • Penston J (2003) Fiction and fantasy in medical research. the large scale randomised trial. The London Press, London

    Google Scholar 

  • Peto R, Collins R, Gray R (1995) Large scale randomized evidence: Large simple trials and overviews of trials. J Clin Epidemiol 48:23–40

    Article  Google Scholar 

  • Rawlins M (2008) De Testimonio: On the evidence for decisions about the use of therapeutic interventions. Royal College of Physicians. http://www.rcplondon.ac.uk/pubs/brochure.aspx? e = 262. Accessed 18 December 2008

  • Tukey JW (1977) Some thoughts on clinical trials, especially problems of multiplicity. Science 198:679–684

    Article  Google Scholar 

  • Worrall J (2002) What evidence in evidence-based medicine? Philos Sci 69:S316–S330

    Article  Google Scholar 

  • Worrall J (2007a) Why there’s no cause to randomize. Br J Philos Sci 58:451–488

    Article  Google Scholar 

  • Worrall J (2007b) Evidence in medicine and evidence-based medicine. Philos Compass 2(6):981–1022

    Article  Google Scholar 

  • Worrall J (2008) Evidence and ethics in medicine. Perspect Biol Med 51:418–431

    Article  Google Scholar 

  • Yusuf S, Collins R, Peto R (1984) Why do we need some large, simple randomized trials? Statist Med 3:409–420

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Worrall, J. (2010). Do We Need Some Large, Simple Randomized Trials in Medicine?. In: Suárez, M., Dorato, M., Rédei, M. (eds) EPSA Philosophical Issues in the Sciences. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-3252-2_27

Download citation

Publish with us

Policies and ethics